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abstract: Objectives: Molecular diagnostic laboratories screen for mutations in disease-causing genes in order 
to confirm a clinical diagnosis. The classification of DNA variants as ‘pathogenic’ or ‘likely pathogenic’ mutations 
creates a workflow bottleneck, which becomes increasingly challenging as greater number of genes are screened. 
The classification challenge is also acute if there are conflicting reports regarding pathogenicity and differing 
classification criteria between laboratories. This study aimed to compare two procedures for the classification 
of variants in the breast cancer (BRCA)1 gene. Methods: This bioinformatic study was conducted at LabPLUS, 
Auckland, New Zealand, from February to June 2017. DNA was extracted from peripheral blood samples of 30 
patients and gene library construction was carried out using a commercially available targeted panel for the BRCA1 
and BRCA2 genes. The genes were subsequently sequenced and the sequence data analysed. The guidelines published 
by the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/
AMP) provides a comprehensive framework for the interpretation of variants in genes that are associated with 
Mendelian disorders. The use of these guidelines were compared to the variant classifications that were achieved 
by reference to those reported in the BRCA Exchange database. Results: The results showed concordance between 
the two classification protocols for a panel of 30 BRCA1 gene variants, although the transparency in following the 
ACMG/AMP guidelines provides a diagnostic laboratory with a generalisable approach that allows laboratory-
directed revisions to be undertaken in light of new information. Conclusion: The ACMG/AMP-based guidelines 
were applied to a cohort of patients with BRCA1 gene variants. The use of these guidelines provides a system which 
creates consistency in variant interpretation and supports subsequent clinical management.
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الت�صخي�ض  تاأكيد  بغر�ض  للمر�ض  املحدثة  املورثات  بالتحري عن وجود طفرات يف  اجلزيئي  الت�صخي�ض  معامل  تقوم  الهدف:  امللخ�ص: 
الكلينيكي. ويف�صي ت�صنيف متغريات احلم�ض الريبي النووي املنزوع الأوك�صجني )دنا( اإىل كونها متغريات )ممر�صة( اأو )يحتمل اأن تكون 
ممر�صة( لختناق �صري العمل. وهو حتٍد يزداد �صعوبة مع زيادة عدد املورثات التي ينبغي فح�صها. وكذلك يغدو ع�رس الت�صنيف اأكرث حدًة اإذا 
كانت هنالك تقارير مت�صاربة من خمتلف املعامل حول حتديد الإمرا�صية ومعايري الت�صنيف نف�صها. وتهدف هذه الدرا�صة ملقارنة طريقتني 
لت�صنيف املتغريات اجلينية ملورث براكا 1. الطريقة: اأجريت هذه الدرا�صة املعلوماتية احليوية يف خمتربات )لب بل�ض( يف اوكالند بنيوزيلندا 
بني فرباير ويونيو من عام 7102م. ومت يف هذه الدرا�صة ا�صتخال�ض دنا من عينات دم طرفية لثالثني مري�صا، وان�صاأت مكتبة مورثات با�صتخدام 
لوحة م�صتهدفة ملورثات ال�رسطان براكا 1 وبراكا 2 متوفرة جتاريا. ومت عمل ت�صل�صل تتابعي لها وحتليل املعلومات امل�صتقاة. تقدم الدلئل 
الر�صادية التي اأ�صدرتها الكلية الأمريكية لعلم اجلينوم الطبي وجمعية علم الأمرا�ض اجلزيئي اإطارا �صامال لتف�صري املتغريات اجلينية املرتبطة 
بالأمرا�ض امَلْنِدِليَّة. متت مقارنة نتائج ا�صتخدام النوعني من الدلئل الر�صادية لت�صنيف املتغريات اجلينية املتح�صل عليها يف قاعدة بيانات 
)براكا( التبادلية. النتائج: اأثبتت النتائج وجود اتفاق بني الت�صنيفني يف لوحة مكونة من ثالثني متغريا جينيا لرباكا 1. غري اأن �صفافية اللتزام 
بالدلئل الر�صادية التي اأ�صدرتها الكلية الأمريكي لعلم اجلينوم الطبي وجمعية علم الأمرا�ض اجلزيئي توفر ملعمل الت�صخي�ض نهجا معمما 
تتيح اإمكانية املراجعة والتعديل يف النتائج حني ظهور معلومات جديدة. اخلال�صة: ا�صتخدمت الدلئل الر�صادية التي اأ�صدرتها الكلية الأمريكية 
لعلم اجلينوم الطبي وجمعية علم الأمرا�ض اجلزيئي يف ت�صخي�ض املتغريات اجلينية لرباك 1 عند فئة من املر�صى. يوفر ا�صتخدام تلك الدلئل 
الر�صادية ات�صاقا يف تف�صري املتغريات اجلينية، ويوؤازر التدابري العالجية الإكلينيكية الالحقة.
الكلمات املفتاحية: مورث براك 1؛ املعلوماتية احليوية؛ ت�صلل دانا التتابعي؛ راِمَزٌة ُهَراِئيَّة؛ موقع مانح الو�صلة؛ نيوزيلندا. 
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Breast cancer is the most common malignancy among women, both in developed and developing countries, accounting for one 
in ten of all new cancers diagnosed worldwide.1 Approx- 
imately 5% of breast and ovarian cancers occurs as a result 
of variants in the breast cancer (BRCA)1 gene (MIM# 
113705; NM_007294.3; Locus Reference Genomic 
[LRG]_292), which is localised to the long arm of 
chromosome 17 at band q21 and comprises 23 exons. 
Variants within the BRCA1 gene are associated with 
an 80–90% lifetime risk of breast cancer.2 Patients with 
pathogenic variants in the BRCA1 gene frequently 
have a positive family history of breast and ovarian 
cancer and are often diagnosed at a young age. They 
may also have a higher incidence of double or multiple 
primary breast tumours than breast cancer patients 
in general.3 Another gene implicated in breast cancer, 
BRCA2 (MIM# 600185; NM_000059.3; LRG_293), is 
localised to the long arm of chromosome 13 at band 
q13.1 and comprises 27 exons.4 Patients who carry a 
mutation in the BRCA2 gene have an average risk of 
45% for breast cancer and 11% for ovarian cancer by the 
age of 70 years.5 There is an elevated risk for prostate 
cancer in BRCA2 gene carriers and an increased risk of 
pancreatic, head and neck, stomach and other cancers 
in patients with a mutation in either of these genes.5 
Germline pathogenic variants in both the BRCA1 and 
BRCA2 genes are expressed in an autosomal dominant 
manner.6
Most BRCA1 or BRCA2 gene variants are point 
mutations or small insertions or deletions.7 In 2–12% 
of high-risk families, there may be a large genomic 
rearrangement.5 Therefore, it is important to identify 
patients with disease-causing variants within the BRCA1 
or BRCA2 genes as this may enable early treatment 
options such as surgery, including bilateral prophylactic 
mastectomy or bilateral prophylactic oophorectomy. 
The correct classification of variants is paramount 
in order to avoid invasive outcomes for patients who 
are not at a high risk of developing cancer. Accurate 
classification also determines whether predictive testing 
for other ‘at risk’ family members would be of value.
Standardisation, in terms of variant classification, 
is a complex topic characterised by several challenges 
such as the failure to develop standards, a lack of 
consensus and incompatible implementation of agreed 
standards.8 These issues should be addressed in order 
to provide a consistent framework for reporting variants. 
Identifying a causative variant allows patients and 
families to be aware of the risks and therefore pursue 
appropriate management. If the significance of a 
variant is unknown, then the clinician should decide 
how to deal with this finding for their patient and 
the patient’s relatives. The heightened uncertainty 
resulting from a variant of unknown significance can 
be distressing for patients.9 In order to manage and 
enable consistent and reproducible reporting of these 
variants, the establishment of universal guidelines is 
necessary.
To address the need for internationally stand- 
ardised guidelines for variant nomenclature, a working 
group was set-up to initiate this process.10,11 Currently 
the responsibility for the maintenance and refinement 
of these guidelines is carried out by the Human 
Genome Variation Society (HGVS), and an online tool, 
termed Mutalyzer, has been developed for laboratories 
to check the description of sequence variants.12
Many online tools have become available to assist 
in variant interpretation such as ClinVar (www.ncbi.
nlm.nih.gov/clinvar/), which aggregates information 
about genomic variation and its relationship with 
human health. In addition, the 1000 Genomes Project 
(www.1000genomes.org) and the Exome Aggregation 
Consortium (ExAC; http://exac.broadinstitute.org/), 
the latter being superseded by GnomAD (https://
gnomad.broadinstitute.org/), are useful in obtaining the 
frequencies of variants in large populations. Disease- 
specific databases are also available in order to aid 
standardisation.
In the case of variants detected in the BRCA1/2 
genes, useful online resources include the Breast 
Cancer Information Core (BIC; https://research.nhgri.
nih.gov/bic/) and the ENIGMA consortium (http://
enigma.ini.usc.edu/). An ENIGMA member works 
collaboratively towards the classification of variants 
and contributes data from families with unclassified 
sequence variants and/or conducts statistical analysis 
or laboratory-based assays. Critically, a more global 
and gene-targeted effort in gathering and collating 
data, termed the BRCA Challenge, was launched by the 
Global Alliance for Genomics and Health. As a result 
of the BRCA Challenge, the BRCA Exchange (https://
Advances in Knowledge
- This study reports the use of internationally-accepted criteria for the classification of DNA variants in the context of the breast cancer 1 gene.
Application to Patient Care
- This study emphasises that universally adopted criteria for classifying DNA variants assists in the consistent confirmation of clinical diagnoses and 
the genetic counselling of family members regarding their risks.
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brcaexchange.org/) was launched. This initiative comb- 
ines BRCA1/2 genes variant data from many resources 
such as ClinVar, LOVD (www.lovd.nl/), BIC, ExAC 
(and GnomAD), 1000 Genomes, ESP (http://evs.
gs.washington.edu/EVS), exLOVD and ENIGMA into 
the world’s largest source of non-proprietary BRCA 
variant-level data, which has enabled the expert review 
of thousands of variants. 
Adding to this gene-specific effort, the American 
College of Medical Genetics and Genomics and the 
Association for Molecular Pathology (ACMG/AMP) 
published standards and guidelines for the interpretation 
of sequence variants in 2015.13 These guidelines 
describe a framework for classifying Mendelian variants 
using a list of 28 criteria for determining the impact of a 
variant. With these guidelines, variants are classified as 
‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, 
‘likely benign’ or ‘benign’. 
In the authors’ laboratory, next-generation sequ- 
encing (NGS) analysis using targeted BRCA1 and 
BRCA2 gene panels was validated for diagnostic testing 
in 2014. The ACMG/AMP guidelines were published 
and incorporated into testing at the facility as soon 
as they were published in 2015. This study aimed to 
classify BRCA1 gene variants according to ACMG/
AMP guidelines and compare the classifications to 
those reported in the BRCA Exchange.
Methods
This bioinformatic study was conducted at LabPLUS, 
Auckland, New Zealand, from February to June 2017. 
DNA was extracted from peripheral blood samples 
of 30 patients referred to the Northern hub of the 
Genetic Health Services New Zealand for BRCA1/2 
gene mutation screening. The diagnostic referrals were 
forwarded for testing based on the Cancer Institute 
New South Wales guidelines for genetic testing for 
heritable mutations in the BRCA1 and BRCA2 genes. 
Library construction was carried out using the 
commercially available targeted panel for the BRCA1 
and BRCA2 genes from Multiplicom (Agilent Tech- 
nologies, Inc, The Netherlands). Sequencing was perf- 
ormed using a GS-Junior (Roche Holding AG, Basel, 
Switzerland) platform. Data analysis was undertaken 
using JSI SeqNext software (JSI medical systems GmbH, 
Ettenheim, Germany). In accordance with the AMP 
and College of American Pathologists NGS validation 
guidelines, a minimum of 30 reads was considered 
sufficient for minimum depth of coverage.14 If fewer 
than 30 reads were obtained, Sanger-based sequencing 
was performed to ensure a reliable result. Analysis 
included evaluating the coding regions and exon-intron 
boundaries (±20 base pairs) of the entire BRCA1 gene. 
Alamut® Interactive Biosoftware (www.interactive-
biosoftware.com/doc/alamut-visual/2.6/splicing.html) 
 
Figure 1: Workflow for classification of variants used in the current study (N = 30).
PVS = very strong evidence of pathogenicity; PM = moderate evidence of pathogenicity; PP = supporting evidence of pathogenicity; LSDB = locus-
specific database; BRCA = breast cancer; IARC =International Agency for Research on Cancer; PS = strong evidence of pathogenicity.
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was used to aid in the interpretation of the variants. 
As recommended by the ACMG/AMP guidelines, the 
nomenclature used to describe the variants is based 
on Human Genome Variation Society guidelines. The 
reference sequence for this gene was derived from the 
LRG database. An outline of the approach taken to 
classify the 30 BRCA1 gene variants according to the 
ACMG/AMP guidelines is shown in Figure 1.
The classification categories were assigned by 
applying a series of criteria. The criteria were divided 
into seven attributes based on the ACMG/AMP guide- 
lines. In terms of evidence of pathogenicity these criteria 
were: very strong (PVS1), strong (PS1-4), moderate 
(PM1-6) and supporting (PP1-5). In terms of benign 
impact, the criteria were: stand-alone evidence (BA1), 
strong evidence (BS1-BS4) and supporting evidence 
(BP1-BP7) [Table 1]. The outcome of each call for a 
particular variant was incorporated to give a final score, 
which was used to determine the final classification 
from the five-tiered system [Table 2]. 
Table 1: Criteria used in the investigators’ laboratory for 
variant classifications based on American College of 
Medical Genetics and Genomics and the Association 
for Molecular Pathology guidelines
Criteria Description
PVS1 Frameshift/nonsense/start codon/splice junction ± 2 
base pairs/exonic deletion.
PS1 For missense: the same amino acid change at the same 
codon is known to be pathogenic (different nucleotide 
position). The same amino acid change to be counted 
as strong evidence must also, by ACMG definition, be 
a class 5. If the “other variant” is a class 4, then this evid- 
ence become “moderate” rather than “strong” and can 
only be used to count as supporting evidence for the 
variant of interest to be a class 4 (likely pathogenic). 
PS2 De novo (paternity confirmed) in a patient with the 
disease, no family history and phenotype reasonably 
specific for the disorder.
PS3 Functional study supports damaging effect.
PS4 Prevalence in affected Pts > prevalence in controls–OR 
is statistically significant. Where a significant number 
of cases have been reported carrying the variant and 
showed similar phenotype, it can be used as a “moderate” 
evidence without OR.
PM1 In mutational hot spot/critical domain (without benign 
variations).
PM2 Absent from population databases or extremely low 
MAF. Slightly higher is acceptable for recessive 
conditions.
PM3 For recessive disorders: in trans with known mutation.
PM4 In-frame insertion/deletion in non-repeat region or 
stop-loss variant that results in protein length changes.
PM5 For missense: a known mutation occurs at same codon 
(different amino acid residue). The “known” mutation 
occurred at the same codon must be either a class 4 
or 5 by ACMG definition.
PM6 Not present in parents (i.e. assumed de novo) and 
phenotype reasonably specific for the disorder (without 
confirmation of paternity and maternity).
PP1 Co-segregation with disease (increased weighting 
may be applied if stronger evidence available).
PP2 For missense: in this gene missense variants are usually 
pathogenic.
PP3 Bioinformatic analysis predicts pathogenic (protein 
and/or splice).
PP4 Phenotype is highly specific for this single genetic aetiology.
PP5 A reputable source lists variant as pathogenic but doesn’t 
state how the classification was determined (reput- 
able sources are ClinVar at three or four stars).
BA1 MAF ≥5% in any of the population databases.
BS1 Allele frequency above expected for disorder.
BS2 Found in a healthy individual when full penetrance is 
expected at that age (in correct zygosity for disorder).
BS3 Functional study supports benign effect.
BS4 Doesn’t co-segregate with disease (beware: penetrance).
BP1 For missense: in this gene missense variants are usually 
benign.
BP2 Observed in trans with a pathogenic variant (for domin- 
ant inheritance) or in cis with a pathogenic variant (any 
inheritance pattern).
BP3 In-frame insertion/deletion in a repetitive region 
without a known function.
BP4 Bioinformatic analysis predicts benign (protein and splice).
BP5 Variant found in a case with an alternative molecular 
basis for disease.
BP6 A reputable source lists variant as benign (reputable 
sources are ClinVar at three or four stars): the reput- 
able source must be experts in this disease e.g. a LSDB 
or a lab that has longstanding experience. “No evidence” 
means no evidence of their classification details and 
does not mean no reference at all. Where the classif- 
ication is present but no details on their individual 
criteria, it is considered “no evidence”. The reference 
or paper it cites can still be investigated. However, if the 
detailed criteria is provided, then each evidence must 
be weighted and this option is no longer viable.
BP7 For synonymous/intronic: splice predictions are benign. 
At present, if a synonymous/intronic variant is given 
benign prediction by splice programmes it can be class- 
ified as class 2 without the need to investigate conservation.
PVS = very strong evidence of pathogenicity; PS = strong evidence of patho- 
genicity; ACMG = American College of Medical Genetics and Geno- 
mics; OR = odds ratio; PM = moderate evidence of pathogenicity; PP = supp- 
orting evidence of pathogenicity; BA = stand-alone evidence of benign impact; 
BS = strong evidence of benign impact; BP = supporting evidence of benign 
impact; LSDB = locus-specific database.
Table 2: Criteria used to allocate variants into the five 
American College of Medical Genetics and Genomics 
and the Association for Molecular Pathology classes
Class Requirement
1. Benign BA1 MAF ≥5% or 2 BS
2. Likely benign 1 BS + 1 BP or 2 BS. Only BP7 needed for 
synonymous
3. Uncertain Conflicting information or doesn’t meet 
criteria of another class
4. Likely 
pathogenic
1 PVS + 1 PM; 
1 PS + 1 PM; 
1 PS + 2 PP
3 PM; 
2 PM + 2 PP; 
1 PM + 4 PP
5. Pathogenic 1 PVS + 1 PS; 
1 PVS + 2 PM; 
1 PVS + 1 PM + 1 PP; 
1 PVS + 2 PP
2 PS; 
1 PS + 3 PM; 
1 PS + 2 PM + 2 PP; 
1 PS + 1 PM + 4 PP
BA = stand-alone evidence of benign impact; BS = strong evidence of benign 
impact; BP = supporting evidence of benign impact; PVS = very strong evid- 
ence of pathogenicity; PM = moderate evidence of pathogenicity; PS = strong 
evidence of pathogenicity; PP = supporting evidence of pathogenicity.
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All diagnostic referrals gave informed consent. 
The national multi-region ethics committee of New 
Zealand has ruled that cases of patient management 
do not require formal ethics committee approval. 
Results
A total of 30 variants were classified in this study, of 
which 27 were classified as pathogenic (class 5), two 
variants were classified as likely pathogenic (class 4) 
and one variant was classified as unknown significance 
Table 3: Summary of the patients classified in this study (N = 30)
No. Nucleotide change 
based on HGVS 
nomenclature
Amino acid change 








on the ACMG/AMP 
Guidelines
1 c.66dup p.(Glu23Argfs*18) 2 Pathogenic class 5
2 c.117_118del p.(Cys39*) 3 Pathogenic class 5
3 c.212+1G>T p.? - Not reviewed class 5
4 c.212+2T>C p.? - Not reviewed class 5
5 c.220C>T p.(Gln74*) 5 Pathogenic class 5
6 c.427G>T p.(Glu143*) 6 Pathogenic class 5
7 c.1018del p.(Val340*) 10 Pathogenic class 5
8 c.1298_1299dup p.(Ser434Profs*8) 10 Not reviewed class 4
9 c.1374del p.(Asp458Glufs*17) 10 Not reviewed class 5
10 c.1953dup p.(Lys652Glufs*21) 10 Pathogenic class 5
11 c.1961dup p.(Tyr655Valfs*18) 10 Pathogenic class 5
12 c.2071del p.(Arg691Aspfs*10) 10 Pathogenic class 5
13 c.2074del p.(His692Metfs*9) 10 Pathogenic class 5
14 c.2188_2201del p.(Glu730Thrfs*5) 10 Pathogenic class 5
15 c.2280_2281del p.(Glu761Lysfs*6) 10 Not reviewed class 4
16 c.2447A>G p.(His816Arg) 10 Not reviewed class 3
17 c.2475del p.(Asp825Glufs*21) 10 Pathogenic class 5
18 c.2681_2682del p.(Lys894Thrfs*8) 10 Pathogenic class 5
19 c.3143del p.(Gly1048Valfs*14) 10 Pathogenic class 5
20 c.3254_3255dup p.(Leu1086Aspfs*2) 10 Pathogenic class 5
21 c.3400G>T p.(Glu1134*) 10 Pathogenic class 5
22 c.3607C>T p.(Arg1203*) 10 Pathogenic class 5
23 c.3706_3707del p.(Asn1236Tyrfs*7) 10 Pathogenic class 5
24 c.3718C>T p.(Gln1240*) 10 Pathogenic class 5
25 c.3756_3759del p.(Ser1253Argfs*10) 10 Pathogenic class 5
26 c.3759dup p.(Lys1254*) 10 Pathogenic class 5
27 c.4065_4068del p.(Asn1355Lysfs*10) 10 Pathogenic class 5
28 c.4113del p.(Cys1372Valfs*21) 11 Pathogenic class 5
29 c.4327C>T p.(Arg1443*) 12 Pathogenic class 5
30 c.5152+1G>T p.? - Pathogenic class 5
HGVS = Human Genome Variation Society; BRCA = breast cancer; LRG = locus reference genomic; LSDB = locus-specific database;  ACMG/AMP 
= American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
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Table 4: Criteria used to classify breast cancer 1 gene variants
No. Nucleotide change Type Summary 
of criteria
Evidence used for classification
1
c.66dupA Frameshift PVS1, PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars. 
BRCA exchange pathogenic)
2
c.117_118delTG Nonsense PVS1, PM2, PP5
PVS1 as nonsense (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars. 
BRCA exchange pathogenic)
3
c.212+1G>T Canonical splice site
PVS1, PM2, 
PP3
PVS1 as splice junction ± 2 base pairs 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP3 as in silico evidence predicts splicing to be affected (agreement from all four algorithms 
used in the investigators’ laboratory)†
4
c.212+2T>C Canonical splice site
PVS1, PM2, 
PP3
PVS1 as splice junction ± 2 base pairs 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP3 as in silico evidence predicts splicing to be affected (agreement from 3/4 algorithms 
used in the investigators’ laboratory: MES, NNSplice and HSF)†
5
c.220C>T Nonsense PVS1, PM2, PP5
PVS1 as nonsense (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar)
6
c.427G>T Nonsense PVS1, PM2, PP5
PVS1 as nonsense (predicted to undergo NMD)* 
PM2 as MAF = 0.00010/12 (ExAC); absent from ESP 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
7
c.1018delG Nonsense PVS1, PM2, PP5
PVS1 as nonsense (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
8 c.1298_1299dupCC Frameshift PVS1, PM2 PVS1 as frameshift (predicted to undergo NMD)* PM2 as absent from population databases (1000 Genomes, ExAC and ESP)
9
c.1374delC Frameshift PVS1, PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange not yet reviewed)
10
c.1953dupG Frameshift PVS1, PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
11
c.1961dupA Frameshift PVS1, PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as MAF = 0.000008/1 (ExAC); absent from 1000 genomes and ExAC 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
12
c.2071delA Frameshift PVS1, PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
13
c.2074delC Frameshift PVS1, PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
14
c.2188_2201del14 Frameshift PVS1, PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
15 c.2280_2281delTG Frameshift PVS1, PM2 PVS1 as frameshift (predicted to undergo NMD)* PM2 as absent from population databases (1000 Genomes, ExAC and ESP)
16 c.2447A>G Missense PM2 PM2 as MAF = 0.000008/1 (ExAC); 0.0116/0.0/0.0077 (ESP); MAF = 0.00008/1 (GO-ESP)
17
c.2475delC Frameshift PVS1, PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
18
c.2681_2682delAA Frameshift PVS1, PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
PVS = very strong evidence of pathogenicity; PM = moderate evidence of pathogenicity; PP = supporting evidence of pathogenicity; NMD = nonsense-
mediated decay; BRCA = breast cancer  *NMD prediction based on the premature termination codon not occurring in the 3’ most exon or the 3’-most 
50bp of the penultimate exon;  †Using Splice site prediction programme (www.interactive-biosoftware.com/doc/alamut-visual/2.6/splicing.html), MES 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html), NNSplice (www.fruitfly.org/seq_tools/splice.html) and HSF (www.umd.be/HSF3/).
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(class 3) [Table 3]. The details of evidence used to 
classify each variant are shown in Table 4.
Other than the missense mutation (c.2447A>G), 
the remaining variants were assigned PVS1. The 
rationale for this classification was that all of these 
variants were either nonsense (variants 2, 5–7, 21, 
22, 24, 26 and 29), frameshift (variants 1, 8–15, 17–
20, 23, 25, 27 and 28) or canonical ±1 or 2 splice site 
(variants 3, 4 and 30) variants. The ACMG/AMP 
guidelines assign these variants as PVS1 as they can 
often be assumed to disrupt gene function by leading 
to complete absence of the gene product by lack of 
transcription or nonsense-mediated decay (NMD) 
of the altered transcript.13 Variants predicted not to 
Table 4 (cont.): Criteria used to classify breast cancer 1 gene variants
No. Nucleotide change Type Summary 
of criteria
Evidence used for classification
19 c.3143delG Frameshift PVS1, PM2, 
PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
20 c.3254_3255dupGA Frameshift PVS1, PM2, 
PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
21 c.3400G>T Nonsense PVS1, PM2, 
PP5
PVS1 as nonsense (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
22 c.3607C>T Nonsense PVS1, PM2, 
PP5
PVS1 as nonsense (predicted to undergo NMD)* 
PM2 as MAF = 0.00008/1 (GO-ESP), 0.0/0.0227/0.0077. Absent from 1000 Genomes 
and ExAC 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
23 c.3706_3707delAA Frameshift PVS1, PM2, 
PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
24 c.3718C>T Nonsense PVS1, PM2, 
PP5
PVS1 as nonsense (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
25 c.3756_3759delGTCT Frameshift PVS1, PS4, 
PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PS4 as this variant has been reported in multiple patients with breast and ovarian cancer 
PM2 as MAF = 0.00002/3 (ExAC), MAF = 0.0210/263 (GO-ESP), 2.1934/1.9231/2.1013 (ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
26 c.3759dupT Nonsense PVS1, PM2, 
PP5
PVS1 as nonsense (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
27 c.4065_4068delTCAA Frameshift PVS1, PS4, 
PM2, PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PS4 as this variant is reported in multiple patients with breast and ovarian cancer 
PM2 as MAF = 0.00002/2 (ExAC). Absent from population databases (1000 Genomes and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
28 c.4113delG Frameshift PVS1, PM2, 
PP5
PVS1 as frameshift (predicted to undergo NMD)* 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
29 c.4327C>T Nonsense PVS1, PS4, 
PM2, PP5
PVS1 as nonsense (predicted to undergo NMD)* 
PS4 as this variant is reported to be a common cause of breast and ovarian cancer in the 
French Canandian population but also observed in individuals from other ethnicities. 
PM2 as MAF = 0.00002/3 (ExAC), absent from ESP 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)




PVS1 as splice junction ± 2 base pairs 
PM2 as absent from population databases (1000 Genomes, ExAC and ESP) 
PP3 as in silico evidence predicts splicing to be affected (agreement from all four 
algorithms used in the investigators’ laboratory)† 
PP5 as listed as pathogenic by a reputable source (ClinVar-Pathogenic at three stars; 
BRCA exchange pathogenic)
PVS = very strong evidence of pathogenicity; PM = moderate evidence of pathogenicity; PP = supporting evidence of pathogenicity; NMD = nonsense-
mediated decay; BRCA = breast cancer  *NMD prediction based on the premature termination codon not occurring in the 3’ most exon or the 3’-most 
50bp of the penultimate exon;  †Using Splice site prediction programme (www.interactive-biosoftware.com/doc/alamut-visual/2.6/splicing.html), MES 
(http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html), NNSplice (www.fruitfly.org/seq_tools/splice.html) and HSF (www.umd.be/HSF3/).
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trigger NMD have been defined as those that lead 
to a stop codon 50 nucleotides before or within the 
last exon.15 It is also suggested that variants in close 
proximity to the translation initiation codon can also 
escape NMD due to downstream reinitiation.16 In 
this study, the most 5’ variant was c.66dupA, which 
is in exon 2, 66 nucleotides downstream from the first 
nucleotide; it is therefore not considered very close to 
the translation initiation codon. The most 3’ exon with 
a variant in this gene was in exon 17. Given that exon 
18–23 contain 436 nucleotides, it was concluded that 
none of the current detected variants would prevent 
NMD from occurring. Therefore, PVS1 was assigned 
to each frameshift and nonsense variant. For the three 
splice site variants (variants 3, 4 and 30), Alamut Visual 
software (Interactive Biosoftware, Rouen, France) 
predicted that skipping of exons 4 and 17 was very 
likely. Both exons 4 and 17 are 78 base pairs or 26 
amino acids long. Skipping of these exons would lead 
to an in-frame deletion of this protein, which would 
normally lead to assigning criterion PM4. However, 
exons 4 and 17 encode part of the Really Interesting 
New Gene and BRCA1 C-Terminus domains, which 
are essential for the proteins role as a tumour suppressor.17 
Therefore, the investigators decided that they had 
sufficient evidence to assign criterion PVS1 to these 
three variants.
Variant frequencies were assessed in population 
databases including 1000 genomes, ExAC and ESP. 
Variants were assigned the PM2 criterion if the variant 
was absent or had an extremely low frequency in 
population databases. The databases examined for each 
variant are described in Table 4. In the investigators’ 
laboratory, ClinVar was considered a reputable disease 
database and the PP5 criterion was assigned to any 
variant with a pathogenic interpretation in ClinVar that 
had expert panel review status. Variants designated PP3 
were those in which in silico data had been obtained 
[Table 4]. The PS4 criterion can be assigned to variants 
with an increased prevalence in affected individuals 
compared to the controls. In this study, PS4-assigned 
variants were those that had been reported to be seen 
in multiple patients with breast and ovarian cancer. 
The investigators’ variant classification approach 
led to one variant being classified as class 3; two as 
class 4 and 27 as class 5. In the case of the class 3 
variant (variant 16), it satisfied criterion PM2 as it 
was present at an extremely low frequency in population 
databases. This variant had conflicting evidence for 
pathogenicity in ClinVar as did in silico prediction 
software. In addition, there was an absence of 
publications describing this variant. The two class 4 
variants (variants 8 and 15) were classified as likely 
pathogenic as there was a lack of supporting ClinVar 
evidence and no literature was found describing 
these variants. Table 3 provides a summary of the 
classification together with those present in the BRCA 
Exchange. The classification of variants in the BRCA 
Exchange were concordant with the ACMG/AMP-
based classifications. 
Discussion
The purpose of this study was to classify 30 variants 
detected in the BRCA1 gene according to the ACMG/
AMP guidelines. The variants described in the current 
study were detected prior to the implementation of 
these guidelines, and as a result they had not been 
curated consistently. For the initial classification, a 
variety of online resources had been used such as: the 
BIC database; their ClinVar status and their Inter- 
national Agency for Research on Cancer class. Included 
in the study were seventeen frameshift, nine nonsense, 
three intronic variants and a single missense variant. 
The classification of the variants was weighted 
heavily on the type of variant, the frequency of the 
variant and the ClinVar classification. BRCA1 exhibits an 
autosomal dominant pattern of inheritance.18 Therefore, 
a heterozygous variant has potential to cause disease. The 
majority of clinically significant deleterious mutations 
within the BRCA1 and BRCA2 genes have been 
reported to be protein-truncating mutations, while a 
small number are missense mutations.5 The majority 
of variants in this study were either frameshift or 
nonsense mutations. The investigators’ interpretation 
of the ACMG/AMP guidelines enabled the majority 
(97%) of the variants to be assigned PVS1. 
The criteria were sufficient to enable all but one of 
the variants to be classified as either ‘likely pathogenic’ 
or ‘pathogenic’, thus providing an informative result for 
clinicians who could focus on the clinical management 
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of patients with these variants in the future. Use of the 
current methodology based on ACMG/AMP variant 
classification guidelines gave final calls with a high level of 
concordance to well-curated locus-specific databases. 
All 24 variants in this study that were listed as patho- 
genic by the BRCA Exchange were also classified as 
class 5 pathogenic variants.
Recent evaluations of the ACMG/AMP guidelines 
have been published.19,20 One study examined the class- 
ification findings across nine laboratories in the USA.19 
Although these findings showed that the use of the 
ACMG/AMP guidelines did not initially improve inter-
laboratory concordance, they did provide a common 
framework to facilitate resolution of the differences 
when discussed subsequently.19 In addition, Maxwell 
et al. classified 1,640 variants and summarised that 
their findings supported the clinical utility of ACMG/
AMP variant-classification guidelines.20 Outside of the 
USA, other countries are adopting these guidelines. In 
November 2016, a consensus statement was issued by 
the Association for Clinical Genomic Science (ACGS). 
It recommended use of the ACMG/AMP guidelines 
for germline variant classification and interpretation 
in UK diagnostic genetic laboratories performing 
testing of rare disease and familial cancers.21 This 
development highlights that there is an international 
effort in place to standardise variant interpretation. 
These guidelines were recognised to provide a starting 
point for further refinements and extensions in the 
future.22 The Sequence Variant Interpretation (SVI) 
Working Group has begun this process, taking on 
the task of improving the current ACMG/AMP 
recommendations in order to develop quantitative 
approaches to variant interpretation. As a result of 
this, the ACGS published best practice guidelines for 
variant classification in 2018.21
According to the ACMG/AMP guidelines, 
the PVS1 criterion provides a very strong level of 
confidence in assigning pathogenicity; however, there 
are certain caveats to this criterion. The factors to 
take into consideration when assigning PVS1 include: 
ensuring that loss of function is a known disease 
mechanism; using caution when interpreting loss 
of function variants at the extreme 3’ end of a gene; 
attention to splice variants that are predicted to 
lead to exon skipping but leave the remainder of the 
protein intact; the presence of multiple transcripts 
and assuming that a null variant will lead to disease 
if found in an exon where no other pathogenic 
variants have been described. Due to concerns that 
inappropriate use of this criterion may have a signif- 
icant impact on a patient’s well-being, the SVI working 
group has produced recommendations for interpreting 
the loss of function PVS1 ACMG/AMP variant criterion.23 
These recommendations provide a detailed description 
of the types of variants that can be assigned this 
classification, as well as a decision tree to aid in variant 
interpretation.
The PP5 criterion was frequently used in the 
current study. This criterion requires that a reputable 
source lists the variant as pathogenic but doesn’t state 
how the classification was determined. This criterion 
is appropriate when information is obtained from a 
clinical laboratory that has long-standing expertise 
in the disease area. Within the current laboratory, it 
was thought appropriate to apply PP5 when there was 
a ClinVar review with three stars supporting patho- 
genicity. The SVI working group suggested that PP5 
(along with its benign equivalent, BP6) be removed 
from the criteria. This is due to the fact that ClinVar 
has become so successful that submissions with 
‘assertion criteria provided’ account for the majority 
of cases uploaded and that sufficient primary evidence 
is now available.22
The PP3 criterion was used in this study alongside 
PVS1 for intronic variants. Although not stated in the 
ACMG/AMP guidelines, the SVI working group has 
suggested avoiding using PP3 together with PVS1 as 
the evidence is based on the same set of data and has 
the potential to lead to errors in classification.23 If that 
suggestion had been followed in the current study, two 
of the three canonical splice site variants (variants 3 
and 4) would be reclassified as class 4 (from class 5) 
but the remaining variant (variant 30) would remain 
a class 5.
Table 5 summarises the implications to the 
laboratory and to the clinic regarding the consequences 
of variant classification. Having the ACMG/AMP 
guidelines in place allows the laboratory to assign an 
appropriate frequency of revisions. 
As discussed above, refinement of the ACMG/
AMP  guidelines has already began and will continue to 
evolve over time. Within the investigators’ laboratory, 
the development of a work-up document for internal 
use following the ACMG/AMP guidelines has enabled 
a more systematic approach to variant interpretation 
and proved a useful resource in achieving rigour 
regarding variant classification. The refinement of these 
guidelines will continue to improve the interpretation 
of variants, ultimately leading to an improvement in 
patient care.
For the classification of variants in this study the 
following criteria were not used: PS2 (de novo-paternity 
confirmed); PM6 (assumed de novo, but without 
confirmation); PP1 (co-segregation with disease); BS4 
(lack of segregation in affected members) and PP4 
(patient’s phenotype or family history is highly specific 
for a disease with a single genetic aetiology). Information 
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was not available regarding family history, the inheritance 
of the variants or the patients’ clinical status. Although 
the majority of the variants described here were classified 
as pathogenic without this additional information, this is 
not always going to be the case and the availability of 
as much information as possible is essential to provide 
accurate variant classification.
The advantage of an approach that adheres to 
international guidelines is the acknowledgement that 
variant classification requires objectivity but recognising 
that best practice is aspirational. While the BCRA 
Exchange classifications were used as a benchmark, 
recent work of Cusin et al. provides a salutary lesson.24 
These authors highlight the importance of including 
information regarding the molecular and cellular impacts 
of variants, which need to be retrieved in a comput- 
ationally accessible format.24 This is especially so for 
class 3 variants that currently suffer from a paucity of 
functional data, as well as limited clinical impact data 
due to the logistic challenges of performing familial 
segregation analysis. Diagnostic laboratories should 
play a larger role in addressing the latter, while research 
laboratories should address the former.
Conclusion
The use of ACMG/AMP guidelines for the class- 
ification of DNA variants allows a diagnostic labor- 
atory to benchmark their classifications against other 
laboratories so as to achieve consistency in outcomes. 
This benchmarking also enables clinicians to have 
confidence in the veracity of diagnostic reports and 
provides a transparent process that is subject to 
objective evidence. 
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